UBS keeps USD 400.00 target for Cigna Group stock
Published on 10/14/2026 at 14:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and quarterly revenue
- UBS reiterated its USD 400.00 price target and Buy rating for Cigna Group on October 1, 2026.
- Second-quarter 2026 revenue reached USD 71.70 billion versus USD 70.18 billion consensus.
- Cigna Group stock costs EUR 254.05 at Lang & Schwarz on October 14, 2026 at 1:48 p.m. CEST.
- The stock's market capitalization was USD 74.7 billion and its P/E ratio was 11.69.
UBS reiterated a Buy rating and a USD 400.00 price target for Cigna Group stock on October 1, 2026, according to Investing.com. Against the USD 282.53 primary-exchange quote dated October 13, 2026, that target was 41.57 percent higher. Cigna Group stock was trading at EUR 254.05 at Lang & Schwarz on October 14, 2026 at 1:48 p.m. CEST.
Second-quarter revenue beats consensus
Cigna reported USD 71.70 billion of revenue for the second quarter of 2026, above the USD 70.18 billion consensus cited by Investing.com. Adjusted earnings per share reached USD 7.78, compared with a USD 7.59 forecast, giving the quarterly report a second quantified comparison.
Price remains below yearly high
The primary-exchange quote was USD 282.53 on October 13, 2026, while the 52-week range stood at USD 239.51 to USD 311.34. The current euro quotation therefore sits in a separate currency frame, and the 52-week range is not netted against it. Finance data put Cigna's market capitalization at USD 74.7 billion, with a P/E ratio of 11.69 and a dividend yield of 2.00 percent.
On October 1, 2026, Investing.com reported that Cigna reaffirmed its 2026 outlook, including adjusted revenue of approximately USD 280 billion and adjusted earnings per share of at least USD 30.45. The same report cited a USD 3.00 billion modernization and productivity initiative through 2030.
Comparison with peers
Cigna Group (NYSE, USD): minus 0.29 percent, P/E 11.69, market capitalization USD 74.7 billion.
UnitedHealth Group (NYSE, USD): minus 0.20 percent, P/E 21.56, market capitalization USD 343.1 billion.
Elevance Health (NYSE, USD): plus 0.75 percent, P/E 18.90, market capitalization USD 92.2 billion.
Valuation and reporting calendar
The latest available calendar reference identified by Barron's placed the third-quarter 2026 report on October 29, 2026. The valuation mix is clear: Cigna's P/E of 11.69 was below UnitedHealth Group's 21.56 and Elevance Health's 18.90.
Trading reference for investors
Lang & Schwarz showed Cigna Group stock at EUR 254.05 on October 14, 2026 at 1:48 p.m. CEST. The quote was an intraday value, while the primary-exchange context was USD 282.53 on October 13, 2026.
Market context: Market report S&P 500.
The further course of trading is shown by the continuously updated real-time quote of Cigna Group stock.
Cigna Group stock facts
- Company: Cigna Corporation
- ISIN: US1255231003
- Ticker: CI
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 14, 2026, 1:48 p.m. CEST: EUR 254.05
- Market capitalization: USD 74.7 billion as of October 13, 2026
- 52-week range: USD 239.51-311.34 as of October 13, 2026
- Sector / Industry: Healthcare / Medical - Healthcare Plans
